×

It’s not goodbye, it’s hello Magnifi!

You are now leaving a Magnifi Communities’ website and are going to a website that is not operated by Magnifi Communities. This website is operated by Magnifi LLC, an SEC registered investment adviser affiliated with Magnifi Communities.

Magnifi Communities does not endorse this website, its sponsor, or any of the policies, activities, products, or services offered on the site. We are not responsible for the content or availability of linked site.

Take Me To Magnifi

StockNews.com

4 Stocks Investors Should Limit Their Exposure to This Winter

The broader market has taken a beating this year due to various macroeconomic and geopolitical headwinds, including sky-high inflation, the economic fallout from Russia’s invasion of Ukraine, and increasing recessionary fears. The S&P 500 is down 16.2% year-to-date, while the Nasdaq Composite has plunged 28.6%. The Federal Reserve yesterday increased its benchmark interest rate by

4 Stocks Investors Should Limit Their Exposure to This Winter Read More »

1 Fashion Stocks to Buy This Holiday and 1 to Avoid

Despite macro headwinds, the fashion and apparel industry continues to witness stable demand. According to Adobe, online shoppers spent a record $5.29 billion on Thanksgiving 2022, an increase of 2.9% year over year. They spent most on toys, apparel, grills, and outdoor equipment. “What we are seeing is the discounts being strong enough to entice

1 Fashion Stocks to Buy This Holiday and 1 to Avoid Read More »

The Best Blue-Chip Stock to Buy for 2023 and Beyond

This year, sky-high inflation and the Federal Reserve’s attempts to tame it have caused significant market volatility. The central bank is expected to raise interest rates again this month by 0.5 percentage points. Well-established and financially sound companies, called “blue chips,” weather a market downturn better than smaller companies, making them solid picks in the

The Best Blue-Chip Stock to Buy for 2023 and Beyond Read More »

1 Pharma Stock to Buy for Under $1 This December

Rigel Pharmaceuticals (RIGL) surpassed EPS estimates by 18.5% for its 2022 third quarter. Moreover, the U.S. Food and Drug Administration approved its REZLIDHIA (olutasidenib) capsules for treating adult patients with relapsed or refractory (R/R) acute myeloid leukemia. REZLIDHIA is expected to be incredibly beneficial for patients with poor prognoses and is a solid addition to

1 Pharma Stock to Buy for Under $1 This December Read More »

3 Popular Stocks Investors Have Been Busy Selling Short

The stock market and economy have struggled significantly this year due to multi-decade high inflation, aggressive monetary policy tightening by the Federal Reserve, the economic fallout from Russia’s invasion of Ukraine, and the growing possibility of a recession. The Fed raised interest rates this year at the fastest since the 1980s, including 75 basis point

3 Popular Stocks Investors Have Been Busy Selling Short Read More »